These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17580855)

  • 21. HPFP, a model propellant for pMDIs.
    Rogueda PG
    Drug Dev Ind Pharm; 2003 Jan; 29(1):39-49. PubMed ID: 12602491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics.
    Selvam P; Bharatwaj B; Porcar L; da Rocha SR
    Int J Pharm; 2012 Jan; 422(1-2):428-35. PubMed ID: 22044539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting physical stability in pressurized metered dose inhalers via dwell and instantaneous force colloidal probe microscopy.
    D'Sa D; Chan HK; Chrzanowski W
    Eur J Pharm Biopharm; 2014 Sep; 88(1):129-35. PubMed ID: 25058596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
    Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
    J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers.
    Liao YH; Brown MB; Jones SA; Nazir T; Martin GP
    Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers.
    D'Sa D; Chan HK
    Curr Pharm Des; 2015; 21(27):3955-65. PubMed ID: 26290200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reformulation of Stmerin(®) D CFC formulation using HFA propellants.
    Murata S; Izumi T; Ito H
    Pharm Dev Technol; 2013; 18(6):1314-8. PubMed ID: 22519407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
    Hoe S; Young PM; Rogueda P; Traini D
    AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers.
    Nyambura BK; Kellaway IW; Taylor KM
    Int J Pharm; 2009 Jun; 375(1-2):114-22. PubMed ID: 19481697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel pMDI formulations for pulmonary delivery of proteins.
    Li HY; Seville PC
    Int J Pharm; 2010 Jan; 385(1-2):73-8. PubMed ID: 19854252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding solvation in the low global warming hydrofluoroolefin HFO-1234ze propellant.
    Yang L; da Rocha SR
    J Phys Chem B; 2014 Sep; 118(36):10675-87. PubMed ID: 25137437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers.
    Ju D; Shrimpton J; Hearn A
    Int J Pharm; 2010 May; 391(1-2):221-9. PubMed ID: 20227471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation.
    Wu L; da Rocha SR
    Langmuir; 2007 Nov; 23(24):12104-10. PubMed ID: 17958454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of metered dose inhaler (MDI) formulations of ciclosporin.
    Marijani R; Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2007 Jan; 59(1):15-21. PubMed ID: 17227616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers.
    Selvam P; El-Sherbiny IM; Smyth HD
    J Aerosol Med Pulm Drug Deliv; 2011 Feb; 24(1):25-34. PubMed ID: 20961166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers.
    Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
    Eur J Pharm Biopharm; 2012 May; 81(1):74-81. PubMed ID: 22245573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rejuvenated pressurised metered dose inhaler.
    Bell J; Newman S
    Expert Opin Drug Deliv; 2007 May; 4(3):215-34. PubMed ID: 17489650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surfactant solubility and aggregate orientation in hydrofluoroalkanes.
    Ridder KB; Davies-Cutting CJ; Kellaway IW
    Int J Pharm; 2005 May; 295(1-2):57-65. PubMed ID: 15847991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.